KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Interest Expenses (2019 - 2025)

Rigel Pharmaceuticals has reported Interest Expenses over the past 9 years, most recently at $1.7 million for Q4 2025.

  • Quarterly results put Interest Expenses at $1.7 million for Q4 2025, down 13.09% from a year ago — trailing twelve months through Dec 2025 was $7.3 million (down 7.55% YoY), and the annual figure for FY2025 was $7.3 million, down 7.55%.
  • Interest Expenses for Q4 2025 was $1.7 million at Rigel Pharmaceuticals, down from $1.9 million in the prior quarter.
  • Over the last five years, Interest Expenses for RIGL hit a ceiling of $2.1 million in Q3 2024 and a floor of $485000.0 in Q1 2021.
  • Median Interest Expenses over the past 5 years was $1.8 million (2021), compared with a mean of $1.5 million.
  • Biggest five-year swings in Interest Expenses: surged 398.3% in 2021 and later crashed 67.65% in 2022.
  • Rigel Pharmaceuticals' Interest Expenses stood at $1.3 million in 2021, then dropped by 14.78% to $1.1 million in 2022, then soared by 72.27% to $1.9 million in 2023, then increased by 2.52% to $2.0 million in 2024, then dropped by 13.09% to $1.7 million in 2025.
  • The last three reported values for Interest Expenses were $1.7 million (Q4 2025), $1.9 million (Q3 2025), and $1.9 million (Q2 2025) per Business Quant data.